Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME
Anti-Notch1 safely exerts anti-melanoma effects and improves immune checkpoint inhibitor efficacy. Thus, anti-Notch1 could represent a novel addition to the immunotherapy repertoire for melanoma.
Authors
- María Beatriz Álvarez Flores (ORCID: https://orcid.org/0000-0002-0292-5010)
- Keman Zhang (ORCID: https://orcid.org/0000-0002-1872-2875)
- Giuseppe Ingrasci (ORCID: https://orcid.org/0000-0003-1322-0689)
- Zoe M. Lipman
- Vijay S. Thakur (ORCID: https://orcid.org/0000-0001-5298-963X)
- Barbara Bedogni (ORCID: https://orcid.org/0000-0002-1539-9064)
- Juliano T. Freitas (ORCID: https://orcid.org/0000-0003-0267-807X)
- Hong Qiu (ORCID: https://orcid.org/0000-0002-4088-7828)
- Kathryn M LaPorte
- Thomas R. Malek (ORCID: https://orcid.org/0000-0001-7174-0434)
- Varsha Thakur (ORCID: https://orcid.org/0000-0002-7484-6856)
- Valentina Caicedo
- Chioma G. E. Ajaegbu
Institutions
- University of Miami (US)
- Sylvester Comprehensive Cancer Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1186/s13046-024-03214-5
- Citations
- 4
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Melanoma Research Alliance
- University of Miami
- Bankhead-Coley Foundation
- Sylvester Comprehensive Cancer Center, University of Miami Health Systems
- National Institutes of Health
- Miami Center for AIDS Research
- Center for AIDS Research, University of Washington
- Leonard M. Miller School of Medicine
- National Cancer Institute